# US 2006/0153859 A1 · Ganglioside-KLH conjugate vaccine with QS-21

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153859 A1
- Document ID: US20060153859A1
- Status: Published application
- Kind: A1
- Application number: 11/375,549
- Filed: 2006-03-13
- Published: 2006-07-13
- Earliest claimed: 1995-11-16
- Assignees: Sloan-Kettering Institute for Cancer Research
- Inventors: Philip Livingston; Friedhelm Helling
- Web page: https://patentgrep.com/patent/US20060153859A1

## CPC

- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 39/001171: {Gangliosides, e.g. GM2, GD2 or GD3}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A composition which comprises:
a) a conjugate of (i) a derivative of a GM2 ganglioside, which GM2 ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GM2 ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the GM2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;
b) a saponin; and
c) a pharmaceutically acceptable carrier,
wherein the amount of the conjugated GM2 ganglioside derivative is an amount between about 1 μg and about 200 μg, the amount of the saponin is an amount between about 10 μg and about 200 μg, and the GM2:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of the conjugate and of the saponin being effective to stimulate or enhance production in a subject of an antibody to the GM2 ganglioside.

### Claim 45 (depends on 44)

A method of treating a subject afflicted with a cancer which comprises administering to the subject an amount of the composition of claim 44 effective to stimulate or enhance production in a subject of an antibody to the GM2 ganglioside and to thereby treat the cancer in the subject.

### Claim 46

A method of stimulating or enhancing production of an antibody directed to the GM2 ganglioside in a subject which comprises administering to the subject an effective amount of a composition which comprises:
a) a conjugate of (i) a derivative of a GM2 ganglioside, which GM2 ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GM2 ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the GM2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;
b) a saponin; and
c) a pharmaceutically acceptable carrier,
wherein the amount of the conjugated GM2 ganglioside derivative is an amount between about 1 μg and about 200 μg, the amount of the saponin is an amount between about 10 μg and about 200 μg, and the GM2:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of the conjugate and of the saponin being effective to stimulate or enhance production in a subject of an antibody directed to the GM2 ganglioside.

### Claim 47

A method of treating a human subject having cancer which comprises administering to the subject an effective amount of a composition which comprises:
a) a conjugate of (i) a derivative of a GM2 ganglioside which GM2 ganglioside comprises an unaltered sphingosine base, wherein the derivative differs from the GM2 ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the GM2 ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the GM2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin; and
b) a saponin; and
c) a pharmaceutically acceptable carrier,
wherein the amount of the conjugated GM2 ganglioside derivative is an amount between about 1 μg and about 200 μg, the amount of saponin is an amount between about 10 μg and about 200 μg, the GM2 derivative:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of the conjugate and of the saponin being effective to stimulate or enhance production in a subject of an antibody to the GM2 ganglioside and thereby treat the subject.
